Search Result

Results for "

HDAC+inhibitor

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Adenosine Receptor (1) Akt (2) AMPK (2) Amyloid-β (1) Anaplastic lymphoma kinase (ALK) (1) Androgen Receptor (1) Apoptosis (91) Aurora Kinase (2) Autophagy (38) Bcl-2 Family (5) Bcr-Abl (1) Beta-lactamase (3) Biochemical Assay Reagents (2) c-Fms (1) c-Met/HGFR (1) c-Myc (1) Calcium Channel (2) Carbonic Anhydrase (1) Caspase (6) CDK (2) Cholinesterase (ChE) (1) COX (1) DNA Methyltransferase (2) DNA/RNA Synthesis (4) Drug Derivative (1) Drug Intermediate (4) Drug Metabolite (1) Drug-Linker Conjugates for ADC (2) EBV (1) EGFR (1) Endogenous Metabolite (14) Epigenetic Reader Domain (1) Ferroptosis (3) FLT3 (2) Fungal (1) GSK-3 (1) HDAC (229) HIF/HIF Prolyl-Hydroxylase (1) Histone Acetyltransferase (2) Histone Demethylase (1) HIV (22) iGluR (1) Influenza Virus (1) Isotope-Labeled Compounds (8) JAK (2) Keap1-Nrf2 (1) Ligands for Target Protein for PROTAC (1) MDM-2/p53 (5) Microtubule/Tubulin (7) Mitophagy (16) MMP (1) Monoamine Transporter (1) mTOR (1) NEKs (1) Notch (14) Organoid (6) P-glycoprotein (1) p38 MAPK (2) Parasite (5) PARP (2) PERK (1) Phosphatase (1) Phosphodiesterase (PDE) (2) PI3K (3) Pim (2) Potassium Channel (2) PPAR (1) PROTACs (1) Pyroptosis (1) RAD51 (1) Reactive Oxygen Species (ROS) (7) Reference Standards (15) ROCK (2) SHP2 (1) Sodium Channel (2) STAT (1) Survivin (1) Tau Protein (1) Topoisomerase (1) VD/VDR (1) VEGFR (1) Wee1 (1) Xanthine Oxidase (1)
By Research Areas:	Cancer (204) Cardiovascular Disease (3) Endocrinology (1) Infection (20) Inflammation/Immunology (24) Metabolic Disease (10) Neurological Disease (32)
Click Chemistry:	Azide (1) Alkynes (1)

241

Inhibitors & Agonists

Fluorescent Dyes

Biochemical Assay Reagents

Peptides

Natural
Products

Isotope-Labeled Compounds

Click Chemistry

GMP Molecules

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-12163

Entinostat Maximum Cited Publications 87 Publications Verification MS-275; SNDX-275	HDAC Autophagy Apoptosis	Cancer
Entinostat is an oral and selective class I *HDAC* inhibitor, with IC₅₀s of 243 nM, 453 nM, and 248 nM for *HDAC1, HDAC2, and HDAC3*, respectively.

HY-10225

Belinostat 30+ Cited Publications PXD101; PX105684	HDAC Autophagy	Cancer
Belinostat (PXD101; PX105684) is a potent *HDAC* inhibitor with an IC₅₀ of 27 nM in HeLa cell extracts.

HY-B0246

Carbamazepine 15+ Cited Publications CBZ; NSC 169864	Sodium Channel Autophagy Mitophagy Potassium Channel Calcium Channel HDAC	Neurological Disease Cancer
Carbamazepine is an orally active pressure-sensitive sodium ion channel blocker with an IC₅₀ of 131 μM. Carbamazepine blocks voltage gated Na ⁺, Ca ²⁺, and K ⁺ channels, and is also a *HDAC* inhibitor (IC₅₀: 2 μM). Carbamazepine is an anticonvulsant and can be used for research of epilepsy and neuropathic pain .

HY-14842

Givinostat 10+ Cited Publications ITF-2357	HDAC	Inflammation/Immunology Cancer
Givinostat (ITF-2357) is a *HDAC* inhibitor with an IC₅₀ of 198 and 157 nM for *HDAC1* and *HDAC3*, respectively. Givinostat can be used for Duchenne muscular dystrophy (DMD) research. Givinostat can penetrate the blood-brain barrier (BBB) .

HY-14842B

Givinostat hydrochloride monohydrate 10+ Cited Publications ITF-2357 hydrochloride monohydrate	HDAC	Infection Neurological Disease Inflammation/Immunology Cancer
Givinostat hydrochloride monohydrate (ITF-2357 hydrochloride monohydrate) is a *HDAC* inhibitor with an IC₅₀ of 198 and 157 nM for *HDAC1* and *HDAC3*, respectively. Givinostat hydrochloride monohydrate can penetrate the blood-brain barrier (BBB) .

HY-18361

TMP195 15+ Cited Publications	HDAC	Cancer
TMP195 is a selective class IIa histone deacetylase (HDAC) inhibitor with K_is of 59, 60, 26, 15 nM for HDAC4, HDAC5, HDAC7 and HDAC9, respectively.

HY-10990

Abexinostat 5+ Cited Publications CRA 024781; PCI-24781	HDAC	Cancer
Abexinostat (CRA 024781) is a novel pan-HDAC* inhibitor* mostly targeting HDAC1 with K_i of 7 nM. Abexinostat also inhibits metallo-β-lactamase domain-containing protein 2 (MBLAC2) hydrolase activity with an EC₅₀ below 10 nM .

HY-13322

Pracinostat 5+ Cited Publications SB939	Beta-lactamase HDAC Apoptosis	Cancer
Pracinostat is a potent histone deacetylase (HDAC) inhibitor, with IC₅₀s of 40-140 nM, used for cancer research. Pracinostat also inhibits metallo-β-lactamase domain-containing protein 2 (MBLAC2) hydrolase activity with an EC₅₀ below 10 nM .

HY-13606

Dacinostat 5+ Cited Publications NVP-LAQ824; LAQ824	HDAC Autophagy	Cancer
Dacinostat is a potent *HDAC* inhibitor, with an IC₅₀ of 32 nM; Dacinostat also inhibits *HDAC1* with an IC₅₀ of 9 nM, and used in cancer research.

HY-16425

RG2833 10+ Cited Publications RGFP109	HDAC	Cancer
RG2833 is a brain-penetrant *HDAC* inhibitor with IC₅₀s of 60 nM and 50 nM for HDAC1 and HDAC3, respectively. The K_i values for HDAC1 and HDAC3 are 32 and 5 nM, respectively .

HY-18360

TMP269 15+ Cited Publications	HDAC	Cancer
TMP269 is a novel and selective class IIa histone deacetylase (HDAC) inhibitor with IC₅₀s of 157 nM, 97 nM, 43 nM and 23 nM for HDAC4, HDAC5, HDAC7 and HDAC9, respectively.

HY-15489

Scriptaid 4 Publications Verification Scriptide; GCK1026	HDAC Autophagy Apoptosis Influenza Virus	Cancer
Scriptaid is a potent histone deacetylase (HDAC) inhibitor, used in cancer research. Scriptaid is also a sensitizer to antivirals and has potential for epstein-barr virus (EBV)-associated lymphomas treatment.

HY-16012

Domatinostat tosylate 3 Publications Verification 4SC-202	HDAC Apoptosis	Cancer
Domatinostat tosylate (4SC-202) is a selective class I *HDAC* inhibitor with IC₅₀ of 1.20 μM, 1.12 μM, and 0.57 μM for HDAC1, HDAC2, and HDAC3, respectively. It also displays inhibitory activity against Lysine specific demethylase 1 (LSD1).

HY-149285

NT160	HDAC	Neurological Disease
NT160 is a highly potent class-IIa HDAC inhibitor with an IC₅₀ value of 0.046 μM. NT160 can be used for the research of central nervous system diseases .

HY-14842A

Givinostat hydrochloride 10+ Cited Publications ITF-2357 hydrochloride	HDAC	Inflammation/Immunology Cancer
Givinostat (ITF-2357) hydrochloride is a *HDAC* inhibitor with an IC₅₀ of 198 and 157 nM for *HDAC1* and *HDAC3*, respectively. Givinostat hydrochloride can penetrate the blood-brain barrier (BBB). .

HY-102033

Oxamflatin 1 Publications Verification Metacept-3	HDAC	Cancer
Oxamflatin (Metacept-3) is a potent *HDAC* inhibitor with an IC₅₀ of 15.7 nM. Oxamflatin is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-100748

Zabadinostat 3 Publications Verification CXD101	HDAC	Cancer
Zabadinostat (CXD101) is a potent, selective and orally active class I *HDAC* inhibitor with IC₅₀s of 63 nM, 570 nM and 550 nM for *HDAC1, HDAC2* and *HDAC3, respectively. Zabadinostat has no activity against HDAC* class II. Zabadinostat has antitumor activity .

HY-101780

Tinostamustine 4 Publications Verification EDO-S101; NL-101	HDAC	Cancer
Tinostamustine (EDO-S101) is a pan *HDAC* inhibitor; inhibits *HDAC6, HDAC1, HDAC2* and *HDAC3* with IC₅₀ values of 6 nM, 9 nM, 9 nM and 25 nM, respectively .

HY-158075

*DNMT/HDAC-IN-1*	HDAC DNA Methyltransferase	Cancer
DNMT/HDAC-IN-1 (Compund 15a) is a dual DNMT and *HDAC* inhibitor with IC₅₀ values for HDAC1 and HDAC6 are 56.84 nM and 17.39 nM respectively. DNMT/HDAC-IN-1 can induce apoptosis and be used in tumor research.

HY-13267

Droxinostat 3 Publications Verification NS 41080	HDAC Apoptosis	Cancer
Droxinostat (NS 41080) is a histone deacetylase (HDAC) inhibitor. Droxinostat selectively inhibits HDAC3, HDAC6, and HDAC8 with IC₅₀ values of 16.9 μM, 2.47 μM, and 1.46 μM, respectively. Droxinostat can be used for the research of hepatocellular carcinoma (HCC) .

HY-12954

PTACH NCH-51	HDAC HIV	Infection Cancer
PTACH (NCH-51) is a potent *HDAC* inhibitor with IC₅₀s of 48 nM, 32 nM, and 41 nM for *HDAC1, HDAC4, and HDAC6*, respectively. PTACH exerts potent growth inhibition against various cancer cells (EC₅₀s of 1.1-9.1 μM) .

HY-114483

AES-135 1 Publications Verification	HDAC	Cancer
AES-135, a hydroxamic acid-based pan-HDAC* inhibitor, prolongs survival in an orthotopic mouse model of pancreatic cancer. AES-135 inhibits* HDAC3, HDAC6, HDAC8, and HDAC11 with IC₅₀s ranging from 190-1100 nM .

HY-118672

HNHA	HDAC MMP HIF/HIF Prolyl-Hydroxylase	Cancer
HNHA is a potent *HDAC* inhibitor with an IC₅₀ of 100 nM. HNHA arrests the cell cycle at the G1/S phase via p21 induction. HNHA inhibits tumor growth and tumor neovascularization. HNHA may be a potent anti-cancer agent against breast cancer .

HY-109109

Alteminostat CKD-581	HDAC Apoptosis	Cancer
Alteminostat (CKD-581) is a potent *HDAC* inhibitor. Alteminostat inhibits the class I-II *HDAC* family via histone H3 and tubulin acetylation. Alteminostat can be used for lymphoma and multiple myeloma research .

HY-160092A

Martinostat hydrochloride	HDAC	Neurological Disease
Martinostat hydrochloride is a *HDAC* inhibitor and can be labeled with radionuclides for quantitative imaging of HDACs in vivo in the central nervous system and major peripheral organs .

HY-126856

HC-Toxin	HDAC Apoptosis	Cancer
HC-Toxin, a cyclic tetrapeptide, is a potent *HDAC* inhibitor with an IC₅₀ of 30 nM . HC-Toxin induces tumor cell apoptosis and has anticancer effects .

HY-156602

Bocodepsin OKI-179	HDAC	Cancer
Bocodepsin (OKI-179) is an orally active and selective *HDAC* inhibitor, with antitumor activity. Bocodepsin can be used for suppression on solid tumor and hematologic malignancies .

HY-102083

BRD4884	HDAC	Neurological Disease
BRD4884 is a potent and brain-penetrant *HDAC* inhibitor with IC₅₀ values of 29 nM, 62 nM, and 1090 nM for HDAC1, HDAC2, and HDAC3, respectively. BRD4884 can be used for the study of cognitive impairment .

HY-145613

5-Phenylpentan-2-one	HDAC	Metabolic Disease
5-Phenylpentan-2-one is a potent histone deacetylases (HDACs) inhibitor. 5-Phenylpentan-2-one can be used for urea cycle disorder research .

HY-152174

HDAC-IN-52	HDAC	Cancer
HDAC-IN-52 is a pyridine-containing *HDAC* inhibitor, with IC₅₀s of 0.189, 0.227, 0.440 and 0.446 μM for *HDAC1, HDAC2, HDAC3, and HDAC10, respectively. HDAC*-IN-52 can be used for the research of cancer .

HY-144893

OKI-006	HDAC	Cancer
OKI-006 is an orally active histone deacetylase (HDAC) inhibitor. OKI-006 is the active metabolite of OKI-005 (HY-185584) and OKI-179 (HY-156602). OKI-006 can be used for the research of cancers such as breast cancer and colorectal cancer .

HY-124337

BG48	HDAC	Cancer
BG48 is a potent *HDAC* inhibitor. BG48 inhibits the enzymatic activity of HDAC1 and HDAC2 .

HY-159045

F-SAHA p-Fluoro-SAHA	HDAC	Cancer
F-SAHA is a *HDAC* inhibitor (HDACi) and its ¹⁸F labeled derivative can be used in tumor imaging research .

HY-120508

Pivanex AN-9; Pivalyloxymethyl butyrate	HDAC Bcr-Abl Apoptosis	Inflammation/Immunology Cancer
Pivanex (AN-9), a derivative of Butyric acid, is an orally active *HDAC* inhibitor. Pivanex down-regulates bcr-abl protein and enhances apoptosis. Pivanex has antimetastic and antiangiogenic properties .

HY-161149

CM-1758	HDAC	Cancer
CM-1758 is a histone deacetylase (HDAC) inhibitor. CM-1758 inhibits tumor growth in vivo. CM-1758 induces acetylation of non-histone proteins in acute myeloid leukemia cells .

HY-12163S

Entinostat-d4 MS-275-d₄; SNDX-275-d₄	Apoptosis Autophagy HDAC	Cancer
Entinostat-d₄ is the deuterium labeled Entinostat . Entinostat is an oral and selective class I HDAC inhibitor, with IC₅₀s of 243 nM, 453 nM, and 248 nM for HDAC1, HDAC2, and HDAC3, respectively .

HY-100365

Remetinostat 1 Publications Verification SHP-141	HDAC	Inflammation/Immunology Cancer
Remetinostat (SHP-141) is a hydroxamic acid-based histone deacetylase (HDAC) inhibitor. Remetinostat alleviates Imiquimod (HY-B0180)-induced psoriatic dermatitis. Remetinostat can be used for study of cutaneous T-cell lymphoma .

HY-161050

YSR734	HDAC Apoptosis	Cancer
YSR734 (Compound 21) is a covalent *HDAC* inhibitor with IC₅₀ values of 110 nM, 154 nM, and 143 nM for *HDAC1, HDAC2, and HDAC3, respectively. YSR734 can induce apoptosis* in leukemia cells. YSR734 can induce myoblast differentiation and is used in the study of Duchenne muscular dystrophy .

HY-162086

HDAC-IN-68	HDAC	Cancer
HDAC-IN-68 (Compound 29) is a potent HDAC inhibitor that disrupts microtubule structure and inhibits tumor growth. HDAC-IN-68 significantly inhibits class I HDACs (HDAC1, HDAC2, HDAC3) with IC₅₀ values of 5.1, 11.5 and 8.8 nM, respectively .

HY-106409

Tefinostat 1 Publications Verification CHR-2845	HDAC Apoptosis	Cancer
Tefinostat (CHR-2845) is a monocyte/macrophage targeted histone deacetylase (HDAC) inhibitor. Tefinostat can be cleaved into active acid CHR-2847 by the intracellular esterase human carboxylesterase-1 (hCE-1). Tefinostat can be used for the research of leukaemias .

HY-14842R

Givinostat (Standard) ITF-2357 (Standard)	HDAC Reference Standards	Inflammation/Immunology Cancer
Givinostat (Standard) is the analytical standard of Givinostat. This product is intended for research and analytical applications. Givinostat (ITF-2357) is a HDAC inhibitor with an IC50 of 198 and 157 nM for HDAC1 and HDAC3, respectively. Givinostat can be used for Duchenne muscular dystrophy (DMD) research .

HY-P2228

Chlamydocin (purity≥70%)	HDAC Apoptosis	Cancer
Chlamydocin (purity≥70%), a fungal metabolite, is a highly potent *HDAC* inhibitor, with an IC₅₀ of 1.3 nM. Chlamydocin (purity≥70%) exhibits potent antiproliferative and anticancer activities. Chlamydocin (purity≥70%) induces apoptosis by activating caspase-3 .

HY-155840

KH16	HDAC Apoptosis	Cancer
KH16 is a potent and low nanomolar HDAC inhibitor. KH16 is against class I HDACs HDAC1, HDAC2, and HDAC3, with IC₅₀ values ranging from 6 to 34 nM. KH16 induces cell apoptosis and is against tumor cells with various gene expression patterns .

HY-W095147

2-Acetyl-1-naphthol	Drug Derivative	Others
2-Acetyl-1-naphthol (compound 32) is a naphthol derivative with no *HDAC* inhibitor activity .

HY-160092

Martinostat	HDAC	Neurological Disease
Martinostat is a *HDAC* inhibitor and can be labeled with radionuclides for quantitative imaging of HDACs in vivo in the central nervous system and major peripheral organs .

HY-146153

HDAC-IN-40	HDAC	Cancer
HDAC-IN-40 is a potent alkoxyamide-based *HDAC* inhibitor with K_i values of 60 nM and 30 nM for *HDAC2* and *HDAC6, respectively. HDAC*-IN-40 had antitumor effects .

HY-W017542

L-Pyrohomoglutamic acid	Drug Intermediate Biochemical Assay Reagents	Others
L-Pyrohomoglutamic acid is an amino acid building block. L-Pyrohomoglutamic acid can be used to synthesize ligands for FK506-binding proteins (FKBPs) and histone deacetylase (HDAC) inhibitors .

HY-14842BR

Givinostat hydrochloride monohydrate (Standard) ITF-2357 hydrochloride monohydrate (Standard)	HDAC Reference Standards	Cancer
Givinostat (hydrochloride monohydrate) (Standard) is the analytical standard of Givinostat (hydrochloride monohydrate). This product is intended for research and analytical applications. Givinostat hydrochloride monohydrate (ITF-2357 hydrochloride monohydrate) is a HDAC inhibitor with an IC50 of 198 and 157 nM for HDAC1 and HDAC3, respectively.

HY-118421

Nullscript	Parasite HDAC	Infection
Nullscript is a negative control for Scriptaid. Nullscript is a known inactive analog of Scriptaid . Scriptaid is a representative HDAC inhibitor . Nullscript inhibits Cryptosporidium (C. parvum) growth with the IC₅₀ value of 2.1 μM .

HY-123971

HDAC6 degrader-4	HDAC PROTACs	Cancer
HDAC6 degrader-4 is a PROTAC and a selective *HDAC6* degrader consists of a non-selective HDAC inhibitor and thalidomide-type E3 ligase ligand. HDAC6 degrader-4 can be used for cancer research .

Cat. No.	Product Name	Type

HY-15149G

Romidepsin

FK 228; FR 901228; NSC 630176

Fluorescent Dyes

Romidepsin (GMP) (FK 228 (GMP)) is Romidepsin (HY-15149) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. Romidepsin (FK 228) is a Histone deacetylase (HDAC) inhibitor with anti-tumor activities. Romidepsin (FK 228) inhibits HDAC1, HDAC2, HDAC4, and HDAC6 with IC₅₀s of 36 nM, 47 nM, 510 nM and 1.4 μM, respectively . Romidepsin (FK 228) is produced by Chromobacterium violaceum, induces cell G2/M phase arrest and apoptosis .

HY-10585AG

Valproic acid sodium

Sodium Valproate; VPA sodium; 2-Propylpentanoic acid sodium

Fluorescent Dyes

Valproic acid (Sodium Valproate) sodium is an orally active HDAC inhibitor, with IC₅₀ in the range of 0.5 and 2 mM, also inhibits HDAC1 (IC₅₀, 400 μM), and induces proteasomal degradation of HDAC2. Valproic acid sodium activates Notch1 signaling and inhibits proliferation in small cell lung cancer (SCLC) cells. Valproic acid sodium is used in the treatment of epilepsy, bipolar disorder, metabolic disease, HIV infection and prevention of migraine headaches .

Cat. No.	Product Name	Type

HY-33287

2-Bromothiazole-5-carboxylic acid	Biochemical Assay Reagents
2-Bromothiazole-5-carboxylic acid is a starting compound in the synthesis of active compounds. 2-Bromothiazole-5-carboxylic acid can be used in the synthesis of NAMPT/HDAC inhibitors. 2-Bromothiazole-5-carboxylic acid can be used in the research of colon cancer, lung cancer, and liver cancer .

HY-15149G

Romidepsin

FK 228; FR 901228; NSC 630176

Biochemical Assay Reagents

HY-10585AG

Valproic acid sodium

Sodium Valproate; VPA sodium; 2-Propylpentanoic acid sodium

Biochemical Assay Reagents

Cat. No.	Product Name	Target	Research Area

HY-P2228

Chlamydocin (purity≥70%)	HDAC Apoptosis	Cancer
Chlamydocin (purity≥70%), a fungal metabolite, is a highly potent *HDAC* inhibitor, with an IC₅₀ of 1.3 nM. Chlamydocin (purity≥70%) exhibits potent antiproliferative and anticancer activities. Chlamydocin (purity≥70%) induces apoptosis by activating caspase-3 .

HY-P2698

1-Alaninechlamydocin	HDAC Apoptosis	Cancer
1-Alaninechlamydocin, a cyclic tetrapeptide, is a potent *HDAC* inhibitor (IC₅₀=6.4 nM). 1-Alaninechlamydocin induces G2/M cell cycle arrest and apoptosis in MIA PaCa-2 cells .

HY-P1733

BMf-BH3 BMF-Y	Apoptosis	Cancer
BMf-BH3 (BMF-Y) belongs to the Bcl-2 apoptosis mediator family. BH3-only protein, Bmf is a key molecule for histone deacetylase (HDAC) inhibitors mediated enhancing effect on ionizing radiation-induced cell death .

HY-144292

HDAC-IN-30	HDAC	Cancer
HDAC-IN-30 is a novel multi-target *HDAC* inhibitor, including *HDAC1* (IC₅₀=13.4 nM),HDAC2 (IC₅₀=28.0 nM), *HDAC3* (IC₅₀=9.18 nM), *HDAC6* (IC₅₀=42.7 nM), *HDAC8* (IC₅₀=131 nM). HDAC-IN-30 exhibits potent antitumor efficacy .

HY-P2044

Azumamide E	HDAC	Cancer
Azumamide E is a *HDAC* inhibitor, with an IC₅₀ of 0.064 μM against *HDAC, 1.22 μM against HDAC1, and 2.28 μM against HDAC4. Azumamide E inhibits* *HDAC* activity in nuclear extracts of leukemia cells and cervical adenocarcinoma cells. Azumamide E suppresses angiogenesis. Azumamide E is applicable for research on leukemia, cervical adenocarcinoma, and anti-angiogenesis .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-10585

Valproic acid Maximum Cited Publications 65 Publications Verification VPA; 2-Propylpentanoic acid; Dipropylacetic acid	Infection Structural Classification Classification of Application Fields Ketones, Aldehydes, Acids Metabolic Disease Endogenous metabolite Disease Research Fields Source Classification Cancer	Organoid HDAC Autophagy Mitophagy HIV Notch Apoptosis Endogenous Metabolite
Valproic acid (VPA) is an orally active *HDAC* inhibitor, with IC₅₀ in the range of 0.5 and 2 mM. Valproic acid inhibits *HDAC1* (IC₅₀, 400 μM), and induces proteasomal degradation of *HDAC2. Valproic acid activates Notch1* signaling and inhibits proliferation in small cell lung cancer (SCLC) cells. Valproic acid is used in the epilepsy, bipolar disorder, metabolic disease, HIV infection and prevention of migraine headaches .

HY-10585A

Valproic acid sodium Maximum Cited Publications 65 Publications Verification Sodium Valproate; VPA sodium; 2-Propylpentanoic acid sodium	Infection Classification of Application Fields Ketones, Aldehydes, Acids Metabolic Disease Endogenous metabolite Disease Research Fields Source Classification Cancer	Organoid HDAC Autophagy Mitophagy HIV Notch Apoptosis Endogenous Metabolite
Valproic acid (Sodium Valproate) sodium is an orally active *HDAC* inhibitor, with IC₅₀ in the range of 0.5 and 2 mM, also inhibits *HDAC1* (IC₅₀, 400 μM), and induces proteasomal degradation of *HDAC2. Valproic acid sodium activates Notch1* signaling and inhibits proliferation in small cell lung cancer (SCLC) cells. Valproic acid sodium is used in the treatment of epilepsy, bipolar disorder, metabolic disease, HIV infection and prevention of migraine headaches .

HY-N7676

Marein 3 Publications Verification	Cardiovascular Disease Chalcones Flavonoids other families Neurological Disease Classification of Application Fields Phenols Polyphenols Plants Disease Research Fields Source Classification	AMPK HDAC
Marein has the neuroprotective effect due to a reduction of damage to mitochondria function and activation of the AMPK signal pathway. Marein improves insulin resistance induced by high glucose in HepG2 cells through CaMKK/AMPK/GLUT1 to promote glucose uptake, through IRS/Akt/GSK-3β to increase glycogen synthesis, and through Akt/FoxO1 to decrease gluconeogenesis. Marein is a *HDAC* inhibitor with an IC₅₀ of 100 μM. Marein has beneficial antioxidative, antihypertensive, antihyperlipidemic and antidiabetic effects .

HY-10585B

Valproic acid sodium (2:1) Sodium Valproate (2:1); VPA sodium (2:1); 2-Propylpentanoic acid sodium (2:1)	Infection Classification of Application Fields Ketones, Aldehydes, Acids Metabolic Disease Endogenous metabolite Disease Research Fields Source Classification Cancer	HDAC Autophagy Mitophagy HIV Notch Apoptosis Endogenous Metabolite
Valproic acid (VPA) sodium (2:1) is an orally active *HDAC* inhibitor, with IC₅₀ in the range of 0.5 and 2 mM, also inhibits *HDAC1* (IC₅₀, 400 μM), and induces proteasomal degradation of *HDAC2. Valproic acid sodium (2:1) activates Notch1* signaling and inhibits proliferation in small cell lung cancer (SCLC) cells. Valproic acid sodium (2:1) is used in the treatment of epilepsy, bipolar disorder, metabolic disease, HIV infection and prevention of migraine headaches .

HY-10585AR

Valproic acid sodium (Standard) Sodium Valproate (Standard); VPA sodium (Standard); 2-Propylpentanoic acid sodium (Standard)	Structural Classification Ketones, Aldehydes, Acids Endogenous metabolite Source Classification	Organoid Reference Standards HDAC Autophagy Mitophagy HIV Notch Apoptosis Endogenous Metabolite
Valproic acid (sodium) (Standard) is the analytical standard of Valproic acid (sodium). This product is intended for research and analytical applications. Valproic acid (Sodium Valproate) sodium is an orally active *HDAC* inhibitor, with IC₅₀ in the range of 0.5 and 2 mM, also inhibits *HDAC1* (IC₅₀, 400 μM), and induces proteasomal degradation of *HDAC2. Valproic acid sodium activates Notch1* signaling and inhibits proliferation in small cell lung cancer (SCLC) cells. Valproic acid sodium is used in the treatment of epilepsy, bipolar disorder, metabolic disease, HIV infection and prevention of migraine headaches .

HY-13906

Largazole (+)-Largazole	Structural Classification Natural Products Microorganisms Source Classification	HDAC
Largazole ((+)-Largazole) is a potent, selective, orally active and brain-penetrant class I HDAC inhibitor found in marine cyanobacteria. Largazole shows an IC₅₀ of 0.07 nM for *HDAC2. Largazole releases its active form Largazole thiol (HY-170890) after hydrolysis. Largazole has a strong inhibitory effect on SF-268, SF-295 and SH-SY5Y cells, with IC₅₀ values of 62, 68 and 102 nM respectively Largazole can upregulate the tumor suppressor gene Pax6* to inhibit the proliferation, invasion and colony formation of glioblastoma cells. Largazole can significantly upregulated brain-derived neurotrophic factor BDNF, neuronal transcription factor Pax6, and μ-opioid receptor gene Oprm1. Largazole exerts antitumor and neuroprotective effects. Largazole can be used for researches of Glioblastoma and Alzheimer’s disease .

HY-P2698

1-Alaninechlamydocin	Natural Products Microorganisms Classification of Application Fields Disease Research Fields Cancer Source Classification	HDAC Apoptosis
1-Alaninechlamydocin, a cyclic tetrapeptide, is a potent *HDAC* inhibitor (IC₅₀=6.4 nM). 1-Alaninechlamydocin induces G2/M cell cycle arrest and apoptosis in MIA PaCa-2 cells .

HY-N16881

Andrographidine E	Structural Classification Flavonoids Acanthaceae Flavones Simsia foetida (Cav.) S.F.Blake Plants Source Classification	COX HDAC
Andrographidine E is a COX-2 (IC₅₀ = 19 μM) and *HDAC* inhibitor, with high affinity for HDAC1 and HDAC3. Andrographidine E can specifically bind to macrophages and has potential immunotargeting properties. Andrographidine E can be used for studying inflammation .

HY-P2044

Azumamide E	Structural Classification Peptides Cyclopeptides Marine natural products Sponge Source Classification	HDAC
Azumamide E is a *HDAC* inhibitor, with an IC₅₀ of 0.064 μM against *HDAC, 1.22 μM against HDAC1, and 2.28 μM against HDAC4. Azumamide E inhibits* *HDAC* activity in nuclear extracts of leukemia cells and cervical adenocarcinoma cells. Azumamide E suppresses angiogenesis. Azumamide E is applicable for research on leukemia, cervical adenocarcinoma, and anti-angiogenesis .

Cat. No.	Product Name	Chemical Structure

HY-10585S

Valproic acid-d4

1 Publications Verification

Valproic acid-d₄ is the deuterium labeled Valproic acid. Valproic acid (VPA; 2-Propylpentanoic Acid) is an HDAC inhibitor, with IC₅₀ in the range of 0.5 and 2 mM, also inhibits HDAC1 (IC₅₀, 400 μM), and induces proteasomal degradation of HDAC2. Valproic acid activates Notch1 signaling and inhibits proliferation in small cell lung cancer (SCLC) cells. Valproic acid sodium salt is used in the treatment of epilepsy, bipolar disorder and prevention of migraine headaches .

HY-10585S1

Valproic acid-d6

Valproic acid-d₆ is the deuterium labeled Valproic acid. Valproic acid (VPA; 2-Propylpentanoic Acid) is an HDAC inhibitor, with IC₅₀ in the range of 0.5 and 2 mM, also inhibits HDAC1 (IC₅₀, 400 μM), and induces proteasomal degradation of HDAC2. Valproic acid activates Notch1 signaling and inhibits proliferation in small cell lung cancer (SCLC) cells. Valproic acid sodium salt is used in the treatment of epilepsy, bipolar disorder and prevention of migraine headaches .

HY-10585S2

Valproic acid-d15

Valproic acid-d₁₅ is the deuterium labeled Valproic acid. Valproic acid (VPA; 2-Propylpentanoic Acid) is an HDAC inhibitor, with IC₅₀ in the range of 0.5 and 2 mM, also inhibits HDAC1 (IC₅₀, 400 μM), and induces proteasomal degradation of HDAC2. Valproic acid activates Notch1 signaling and inhibits proliferation in small cell lung cancer (SCLC) cells. Valproic acid sodium salt is used in the treatment of epilepsy, bipolar disorder and prevention of migraine headaches .

HY-12163S

Entinostat-d4
Entinostat-d₄ is the deuterium labeled Entinostat . Entinostat is an oral and selective class I HDAC inhibitor, with IC₅₀s of 243 nM, 453 nM, and 248 nM for HDAC1, HDAC2, and HDAC3, respectively .

HY-10585S4

Valproic acid-d4-1

Valproic acid-d₄-1 is the deuterium labeled Valproic acid. Valproic acid (VPA; 2-Propylpentanoic Acid) is an HDAC inhibitor, with IC₅₀ in the range of 0.5 and 2 mM, also inhibits HDAC1 (IC₅₀, 400 μM), and induces proteasomal degradation of HDAC2. Valproic acid activates Notch1 signaling and inhibits proliferation in small cell lung cancer (SCLC) cells. Valproic acid sodium salt is used in the treatment of epilepsy, bipolar disorder and prevention of migraine headaches .

HY-B0246S4

Carbamazepine-d4

Carbamazepine-d₄ (CBZ-d₄) is the deuterium labeled Carbamazepine (HY-B0246) . Carbamazepine is an orally active pressure-sensitive sodium ion channel blocker with an IC₅₀ of 131 μM. Carbamazepine blocks voltage gated Na ⁺, Ca ²⁺, and K ⁺ channels, and is also a HDAC inhibitor (IC₅₀: 2 μM). Carbamazepine is an anticonvulsant and can be used for research of epilepsy and neuropathic pain.

HY-15149S2

Romidepsin-d7

Romidepsin-d₇ (FK 228-d₇) is deuterium labeled Romidepsin. Romidepsin (FK 228) is a Histone deacetylase (HDAC) inhibitor with anti-tumor activities. Romidepsin (FK 228) inhibits HDAC1, HDAC2, HDAC4, and HDAC6 with IC₅₀s of 36 nM, 47 nM, 510 nM and 1.4 μM, respectively . Romidepsin (FK 228) is produced by Chromobacterium violaceum, induces cell G2/M phase arrest and apoptosis .

HY-10585AS1

Valproic acid-d14 sodium

Valproic acid-d₁₄ (sodium) is deuterium labeled Valproic acid (sodium). Valproic acid sodium salt (Sodium Valproate) is an HDAC inhibitor, with IC50 in the range of 0.5 and 2 mM, also inhibits HDAC1 (IC50, 400 μM), and induces proteasomal degradation of HDAC2. Valproic acid sodium salt activates Notch1 signaling and inhibits proliferation in small cell lung cancer (SCLC) cells. Valproic acid sodium salt is used in the treatment of epilepsy, bipolar disorder and prevention of migraine headaches.

HY-10585AS

Valproic acid-d7 sodium

Valproic acid-d₇ (sodium) is the deuterium labeled Valproic acid (sodium salt). Valproic acid sodium salt (Sodium Valproate) is an HDAC inhibitor, with IC₅₀ in the range of 0.5 and 2 mM, also inhibits HDAC1 (IC₅₀, 400 μM), and induces proteasomal degradation of HDAC2. Valproic acid sodium salt activates Notch1 signaling and inhibits proliferation in small cell lung cancer (SCLC) cells. Valproic acid sodium salt is used in the treatment of epilepsy, bipolar disorder and prevention of migraine headaches .

HY-10585S3

Valproic acid-d4 sodium

Valproic acid-d₄ (sodium) is the deuterium labeled Valproic acid. Valproic acid (VPA; 2-Propylpentanoic Acid) is an HDAC inhibitor, with IC50 in the range of 0.5 and 2 mM, also inhibits HDAC1 (IC50, 400 μM), and induces proteasomal degradation of HDAC2. Valproic acid activates Notch1 signaling and inhibits proliferation in small cell lung cancer (SCLC) cells. Valproic acid sodium salt is used in the treatment of epilepsy, bipolar disorder and prevention of migraine headaches.

HY-10224S

Panobinostat-d4

Panobinostat-d₄ is the deuterium labeled Panobinostat. Panobinostat (LBH589; NVP-LBH589) is a potent and orally active non-selective HDAC inhibitor, and has antineoplastic activities[1][2]. Panobinostat induces HIV-1 virus production even at low concentration range 8-31 nM, stimulates HIV-1 expression in latently infected cells[4]. Panobinostat induces cell apoptosis and autophagy. Panobinostat can be used for the study of refractory or relapsed multiple myeloma[3].

HY-10224S1

Panobinostat-d4 hydrochloride

Panobinostat-d₄ (hydrochloride) is deuterium labeled Panobinostat. Panobinostat (LBH589; NVP-LBH589) is a potent and orally active non-selective HDAC inhibitor, and has antineoplastic activities[1][2]. Panobinostat induces HIV-1 virus production even at low concentration range 8-31 nM, stimulates HIV-1 expression in latently infected cells[4]. Panobinostat induces cell apoptosis and autophagy. Panobinostat can be used for the study of refractory or relapsed multiple myeloma[3].

HY-10225S

Belinostat-d5
Belinostat-d₅ (PXD101-d₅) is the deuterium labeled Belinostat (HY-10225). Belinostat (PXD101; PX105684) is a potent HDAC inhibitor with an IC₅₀ of 27 nM in HeLa cell extracts.

Cat. No.	Product Name		Classification

HY-159112

AW01178		Azide
AW01178 is a Class I *HDAC* inhibitor. AW01178 induces the upregulation of E-cadherin at both mRNA and protein levels and inhibits the EMT of breast cancer cells .

HY-151872

HDAC-IN-48		Alkynes
HDAC-IN-48 is a potent *HDAC* inhibitor. HDAC-IN-48 is a hybrid molecule with great cytotoxic profile (GI₅₀~20 nM). HDAC-IN-48 consists of harmacophores of SAHA and CETZOLE molecules. HDAC-IN-48 induces ferroptosis and inhibits *HDAC* proteins . HDAC-IN-48 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-10585AG

Valproic acid sodium Sodium Valproate; VPA sodium; 2-Propylpentanoic acid sodium	Organoid HDAC Autophagy Mitophagy HIV Notch Apoptosis Endogenous Metabolite	Infection Neurological Disease Metabolic Disease Cancer
Valproic acid (Sodium Valproate) sodium is an orally active *HDAC* inhibitor, with IC₅₀ in the range of 0.5 and 2 mM, also inhibits *HDAC1* (IC₅₀, 400 μM), and induces proteasomal degradation of *HDAC2. Valproic acid sodium activates Notch1* signaling and inhibits proliferation in small cell lung cancer (SCLC) cells. Valproic acid sodium is used in the treatment of epilepsy, bipolar disorder, metabolic disease, HIV infection and prevention of migraine headaches .

HY-15149G

Romidepsin FK 228; FR 901228; NSC 630176	HDAC Apoptosis	Cancer
Romidepsin (GMP) (FK 228 (GMP)) is Romidepsin (HY-15149) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. Romidepsin (FK 228) is a Histone deacetylase (HDAC) inhibitor with anti-tumor activities. Romidepsin (FK 228) inhibits HDAC1, HDAC2, HDAC4, and HDAC6 with IC₅₀s of 36 nM, 47 nM, 510 nM and 1.4 μM, respectively . Romidepsin (FK 228) is produced by Chromobacterium violaceum, induces cell G2/M phase arrest and apoptosis .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

HDAC+inhibitor

Inhibitors & Agonists

Fluorescent Dyes

Biochemical Assay Reagents

Peptides

NaturalProducts

Isotope-Labeled Compounds

Click Chemistry

GMP Molecules

Natural
Products